vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $180.9M, roughly 1.9× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -12.9%, a 12.2% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -0.4%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-680.1M). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
AVNS vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $340.0M |
| Net Profit | $-1.3M | $-13.9M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | -17.2% |
| Net Margin | -0.7% | -12.9% |
| Revenue YoY | 0.7% | -0.4% |
| Net Profit YoY | 99.7% | -131.0% |
| EPS (diluted) | $-0.02 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $340.0M | ||
| Q3 25 | $177.8M | $337.7M | ||
| Q2 25 | $175.0M | $319.2M | ||
| Q1 25 | $167.5M | $237.4M | ||
| Q4 24 | $179.6M | $341.5M | ||
| Q3 24 | $170.4M | $292.3M | ||
| Q2 24 | $171.7M | $270.7M | ||
| Q1 24 | $166.1M | $228.1M |
| Q4 25 | $-1.3M | $-13.9M | ||
| Q3 25 | $-1.4M | $33.5M | ||
| Q2 25 | $-76.8M | $34.0M | ||
| Q1 25 | $6.6M | $2.8M | ||
| Q4 24 | $-397.3M | $44.8M | ||
| Q3 24 | $4.3M | $28.8M | ||
| Q2 24 | $1.8M | $22.7M | ||
| Q1 24 | $-900.0K | $11.9M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | -17.2% | ||
| Q3 25 | 0.1% | 13.6% | ||
| Q2 25 | -42.6% | 14.5% | ||
| Q1 25 | 6.1% | 2.2% | ||
| Q4 24 | -233.0% | 15.3% | ||
| Q3 24 | 7.0% | 12.8% | ||
| Q2 24 | 3.7% | 10.4% | ||
| Q1 24 | 2.4% | 6.0% |
| Q4 25 | -0.7% | -12.9% | ||
| Q3 25 | -0.8% | 9.9% | ||
| Q2 25 | -43.9% | 10.6% | ||
| Q1 25 | 3.9% | 1.2% | ||
| Q4 24 | -221.2% | 13.1% | ||
| Q3 24 | 2.5% | 9.9% | ||
| Q2 24 | 1.0% | 8.4% | ||
| Q1 24 | -0.5% | 5.2% |
| Q4 25 | $-0.02 | $-0.41 | ||
| Q3 25 | $-0.03 | $0.98 | ||
| Q2 25 | $-1.66 | $0.99 | ||
| Q1 25 | $0.14 | $0.08 | ||
| Q4 24 | $-8.64 | $1.32 | ||
| Q3 24 | $0.09 | $0.85 | ||
| Q2 24 | $0.04 | $0.67 | ||
| Q1 24 | $-0.02 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $299.3M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.7B |
| Total Assets | $1.1B | $5.1B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $299.3M | ||
| Q3 25 | $70.5M | $274.8M | ||
| Q2 25 | $90.3M | $233.7M | ||
| Q1 25 | $97.0M | $181.0M | ||
| Q4 24 | $107.7M | $279.3M | ||
| Q3 24 | $89.0M | $179.8M | ||
| Q2 24 | $92.2M | $208.1M | ||
| Q1 24 | $75.8M | $216.5M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $1.7B | ||
| Q3 25 | $778.0M | $1.8B | ||
| Q2 25 | $776.3M | $1.8B | ||
| Q1 25 | $839.4M | $1.7B | ||
| Q4 24 | $828.5M | $1.7B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.2B | $1.7B | ||
| Q1 24 | $1.2B | $1.7B |
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $1.1B | $5.8B | ||
| Q2 25 | $1.0B | $4.7B | ||
| Q1 25 | $1.1B | $4.5B | ||
| Q4 24 | $1.2B | $4.4B | ||
| Q3 24 | $1.7B | $4.6B | ||
| Q2 24 | $1.7B | $4.2B | ||
| Q1 24 | $1.7B | $3.8B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-664.3M |
| Free Cash FlowOCF − Capex | $21.3M | $-680.1M |
| FCF MarginFCF / Revenue | 11.8% | -200.0% |
| Capex IntensityCapex / Revenue | 3.8% | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-664.3M | ||
| Q3 25 | $14.0M | $-948.1M | ||
| Q2 25 | $6.8M | $-238.5M | ||
| Q1 25 | $25.7M | $-281.1M | ||
| Q4 24 | $57.9M | $129.4M | ||
| Q3 24 | $23.0M | $-202.0M | ||
| Q2 24 | $27.8M | $-237.8M | ||
| Q1 24 | $-8.0M | $38.4M |
| Q4 25 | $21.3M | $-680.1M | ||
| Q3 25 | $7.0M | $-950.4M | ||
| Q2 25 | $-4.2M | $-241.0M | ||
| Q1 25 | $19.0M | $-284.7M | ||
| Q4 24 | $53.1M | $116.4M | ||
| Q3 24 | $20.0M | $-204.0M | ||
| Q2 24 | $21.9M | $-241.7M | ||
| Q1 24 | $-12.1M | $35.2M |
| Q4 25 | 11.8% | -200.0% | ||
| Q3 25 | 3.9% | -281.5% | ||
| Q2 25 | -2.4% | -75.5% | ||
| Q1 25 | 11.3% | -120.0% | ||
| Q4 24 | 29.6% | 34.1% | ||
| Q3 24 | 11.7% | -69.8% | ||
| Q2 24 | 12.8% | -89.3% | ||
| Q1 24 | -7.3% | 15.4% |
| Q4 25 | 3.8% | 4.6% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 6.3% | 0.8% | ||
| Q1 25 | 4.0% | 1.5% | ||
| Q4 24 | 2.7% | 3.8% | ||
| Q3 24 | 1.8% | 0.7% | ||
| Q2 24 | 3.4% | 1.4% | ||
| Q1 24 | 2.5% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | 3.89× | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | 5.35× | -7.01× | ||
| Q2 24 | 15.44× | -10.49× | ||
| Q1 24 | — | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
WD
Segment breakdown not available.
